vimarsana.com

Page 215 - மருத்துவ ரீதியாக ஒருங்கிணைந்த வலைப்பின்னல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

YCMH asks police to claim decade-old viscera samples

YCMH asks police to claim decade-old viscera samples YCMH asks police to claim decade-old viscera samples ByVicky PathareVicky Pathare / Updated: Feb 16, 2021, 06:00 IST Hospital authorities write to both PCMC and rural cops to transfer the organs to lab In any suspected murder case or medico-legal case, the viscera report obtained after the post-mortem of the deceased holds prime importance. However, with viscera samples of over 300 deceased people lying in neglect in a locked room of Yashwantrao Chavan Memorial Hospital ( YCMH), it seems that neither Pimpri-Chinchwad police nor Pune rural cops are in any hurry to close these cases. Housing viscera jars of more than 300 bodies, the store wears an almost eerie look, where some of these samples are said to be lying since 2011. Many of the bottles do not even have labels on them anymore to help identify the name of the victim. According to experts, such organs have a 24-hour window to be transferred to a forensic science la

Better Business Bureau warns of scams during Affordable Care Act enrollment period

Basilea Pharmaceutica AG: Basilea reports strong 2020 financial results and significant progress in the clinical pipeline of its oncology assets

Basilea Pharmaceutica AG: Basilea reports strong 2020 financial results and significant progress in the clinical pipeline of its oncology assets Operating loss reduced by over 50% to CHF 8.2 million Improved operating cash flow by 15%, CHF 167 million year-end cash and financial investments Established clinical proof of concept for derazantinib as monotherapy in first cancer indication 2021 guidance: expecting 38% - 51% growth in Cresemba and Zevtera non-deferred revenue contributions, stable expenses and 2021 year-end cash position of CHF 110 - 120 million Basel, Switzerland, February 16, 2021 Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today its financial results for the financial year ended December 31, 2020. David Veitch, Chief Executive Officer, said: Despite the coronavirus pandemic, we have remained fully operational and have achieved significant milestones throughout 2020, both in the commercialization of our two marketed brands, Cresemba and Zevtera, as well

Welcome To IANS Live - NATION - UP to boost herbal cultivation along Ganga banks

According to a government spokesman, the state government has prepared a unique plan with allocation of Rs 4,000 crore to step up organic and zero budget farming in the state and also support its distribution with a dedicated market, which in turn will help farmers living in the adjoining regions by increasing their income up to Rs 500 crore.At p

Monthly cost sharing doubles throughout year for some Medicare insulin users

Date Time Monthly cost sharing doubles throughout year for some Medicare insulin users Over the past decade, the list price of insulin has skyrocketed leading to considerable increases in out-of-pocket spending for Medicare Part D beneficiaries. Despite recent policy efforts to close the Part D coverage gap, Medicare beneficiaries still face monthly out-of-pocket costs that can more than double depending on what phase of the Part D benefit design they are in. Schaeffer Center researchers examined how use of insulin changes as cost-sharing fluctuates over the course of the year. The study, published in JAMA Network Open, found that cost sharing for insulin more than doubled when enrollees moved from the initial coverage phase to the coverage gap. This increase in out-of-pocket spending was associated with reduced adherence- a troubling finding given the importance of insulin for these patients’ health.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.